Filing Flows › Palisade Bio (PALI) › Q2 2026
Palisade Bio (PALI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Palisade Bio (PALI) reported revenue of $500K for the second quarter 2026 (Q2 2026).
Revenue$500K
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$10.6M
Palisade Bio, Q2 2026: revenue $500K, net loss $10.6M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $500K | — | — |
| Operating profit | −$11.7M | — | — |
| Net earnings | −$10.6M | — | — |
| Operating cash flow | −$7.6M | — | — |
What changed
Revenue was $500K in Q2 2026.
Operating costs exceeded revenue by $11.7M, an operating margin of -2339.6%. The quarter ended with a net loss of $10.6M.
Operating cash flow was −$7.6M. Non-cash charges added back $4.8M of share-based compensation. Working capital and other items used $1.8M.
Questions
What was Palisade Bio's revenue in the second quarter 2026?
Palisade Bio (PALI) reported revenue of $500K for the second quarter 2026 (Q2 2026).
Source: Palisade Bio 10-Q on SEC EDGAR.